Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07579208 · ClinicalTrials.gov registry record · Phase 1
A Phase1 Clinical Trial Evaluating Locoregional Delivery Of Engineered NK Cells Containing IL13Ra And EGFvIII Chimeric Antigen Receptor (CAR), IL-21 Secretion And Deleted TGF-BetaR2 And NR3C1 In Recurrent Glioblastoma
A Phase 1 study, sponsored by M.D. Anderson Cancer Center.
- Not yet
- Registry status
- Phase 1
- Development phase
- 36
- Enrollment target
NCT07579208: Clinical Trial Phase 1 study, sponsored by M.D. Anderson Cancer Center.
NCT07579208 is a Phase 1 study that has not yet begun recruiting, run by M.D. Anderson Cancer Center. The registered enrollment target is 36 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07579208, a Phase 1 study, has not yet begun recruiting, sponsored by M.D. Anderson Cancer Center.
- NOT YET RECRUITING
- Registry status
- Phase 1
- Development phase
- 36 participants
- Enrollment target
Study Summary
To find the best method of administering NK cells in patients with recurrent glioblastoma.
Interventions
- DRUG NK Cells
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 36 participants |
| Start Date | 2026-10-24 |
| Est. Completion | 2030-07-30 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07579208
The ClinicalTrials.gov registry entry for NCT07579208 describes a study currently listed as not yet recruiting, categorized as Phase 1. The registered enrollment target is 36 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which NK Cells is the first listed.
NCT07579208 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07579208 about?
NCT07579208 is a clinical study titled "A Phase1 Clinical Trial Evaluating Locoregional Delivery Of Engineered NK Cells Containing IL13Ra And EGFvIII Chimeric Antigen Receptor (CAR), IL-21 Secretion And Deleted TGF-BetaR2 And NR3C1 In Recurrent Glioblastoma". To find the best method of administering NK cells in patients with recurrent glioblastoma.
What is the current status of trial NCT07579208?
This trial is currently not yet recruiting. It is a Phase 1 study. The enrollment target is 36 participants. The study started on 2026-10-24. Estimated completion is 2030-07-30.
What interventions are being tested in trial NCT07579208?
The interventions under investigation include: NK Cells (DRUG).
Who is sponsoring clinical trial NCT07579208?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.